Telesis Bio Q4 EPS $(0.61) Misses $(0.22) Estimate, Sales $6.98M Miss $7.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Telesis Bio (NASDAQ:TBIO) reported Q4 earnings with a significant miss on both EPS and sales estimates. The EPS was $(0.61), missing the $(0.22) estimate by 177.27%, and sales were $6.98M, slightly missing the $7.00M estimate. This represents a 117.86% decrease in EPS and a 26.32% decrease in sales from the same period last year.
March 28, 2024 | 8:33 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Telesis Bio reported a significant miss in Q4 earnings, with EPS and sales not meeting analyst expectations. The EPS miss was particularly large, and both metrics showed a decline from the previous year.
The significant miss in both EPS and sales compared to analyst estimates, coupled with the year-over-year decline in these metrics, suggests a negative outlook for TBIO in the short term. Investors typically react unfavorably to earnings misses, especially when they are as substantial as TBIO's, leading to a likely decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100